AstraZeneca · 3 months ago
Director, Business Planning and Operations
AstraZeneca is shaping the future of cancer science with a robust Oncology R&D pipeline. The Director of Business Planning & Operations will serve as a strategic partner to the VP and Leadership Team, focusing on operational excellence, resource stewardship, and the acceleration of cancer biomarker development.
BiopharmaBiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Be the VP’s trusted advisor—shaping strategy, framing choices, and enabling agile decisions through data-driven insights and functioning in a similar capacity as CoS
Lead business cases & special initiatives—from partnerships and investments to cross-functional change programs including broad adoption of AI and integration of new capabilities and teams
Own budgeting & resource planning—forecasting, prioritization, and portfolio alignment to meet pipeline needs
Drive operational excellence—design leadership rhythms, track actions, and translate strategy into execution
Champion talent & collaboration—support retention, onboarding, and succession planning while fostering a culture of innovation
Qualification
Required
Bachelor's degree and 7+ years in drug or biomarker development, including early-phase portfolio management
Proven experience in business case development, project/program management, and operational leadership
Executive-ready communication skills and ability to influence across functions
Strong analytical mindset; adept at simplifying complex processes
Comfortable in fast-paced, dynamic environments
Preferred
Master's/MBA
Deep Oncology knowledge
Experience leading cross-functional teams
Benefits
Eligibility for various incentives
Short-term incentive bonuses
Equity-based awards for salaried roles
Commissions for sales roles
Qualified retirement programs
Paid time off (i.e., vacation, holiday, and leaves)
Health, dental, and vision coverage
Company
AstraZeneca
AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. It is a sub-organization of Investor.
Funding
Current Stage
Public CompanyTotal Funding
$5.26B2024-07-30Post Ipo Debt· $1.51B
2023-02-28Post Ipo Debt· $2.25B
2023-02-24Post Ipo Debt· $1.5B
Recent News
Essential Business
2026-01-24
2026-01-23
Company data provided by crunchbase